Dolutegravir is manufactured by ViiV/GSK and is used to treat HIV/AIDS. ## Compulsory licenses Compulsory licenses have been issued for Dolutegravir in the following instance: ### Colombia issued on October 01, 2023 [[Colombia]]'s provisions on compulsory licences can be in Decree 1074 of 2015. Compulsory licenses in Colombia can be granted under several circumstances, including: - Public Interest or National Emergency: The government may declare certain situations as matters of public interest or national emergency, justifying the issuance of a compulsory license to ensure public access to essential products or technologies. - Anti-Competitive Practices: If a patent holder engages in anti-competitive practices, such as abuse of dominant position or restrictive trade practices, a compulsory license can be issued to rectify the situation. - Failure to Exploit the Patent: If the patent is not being exploited within the national territory, and the lack of exploitation affects public interest, a compulsory license may be granted to promote the utilization of the patented invention. More information can be found [here](https://www.wipo.int/wipolex/en/legislation/details/18421 ). However, a compulsory license has not been executed for Dolutegravir in this case because: of an unknown reason. ## Other products issued by the same manufacturer [[Dolutegravir]] ## Other products for the same disease [[ARVs]] [[All medicines]] [[EFV]] [[3TC/D4T/NVP]] [[NFV]] [[EFV/FTC/TDF, 3TC/AZT/EFV]] [[RTV]] [[NVP, 3TC, 3TC/AZT]] [[ARVs +]] [[AZT]] [[T-20]] [[DDI, IDV, LPV/r]] [[3TC/AZT/NVP]] [[LPV/r]] [[IDV, LPV/r, NVP, TDF]] [[AZT, 3TC, D4T, NVP, 3TC/AZT]] [[NVP, AZT]] [[3TC/AZT]] [[3TC, D4T, AZT, NVP, EFV, TDF, DDI, LPV/r, SQV, RTV, NFV, ABC]] [[ATV]] [[NVP]] [[ABC/3TC]] [[3TC]] [[3TC, NVP, AZT]] [[NVP, 3TC]] [[3TC, 3TC/AZT, 3TC/AZT/NVP, 3TC/D4T, 3TC/D4T/NVP, DDI, EFV, IDV]] [[AZT, 3TC, AZT/3TC, NVP]] [[RAL]] [[EFV, NVP, 3TC/AZT]] [[3TC/D4T/NVP, LPV/r]] [[TDF/3TC]] [[AZT, 3TC+AZT]]